Focuses on rare and serious kidney diseases, developing treatments to improve the lives of patients.
Travere Therapeutics, Inc. is a dynamic biopharmaceutical firm specializing in the discovery, development, and commercialization of transformative therapies aimed at addressing rare diseases. The company is dedicated to advancing treatment options that cater specifically to underserved patient populations.
Among its established portfolio, Travere Therapeutics markets several notable products. Chenodal, a synthetic oral formulation of chenodeoxycholic acid, stands out for its efficacy in treating radiolucent stones in gallbladders. Cholbam, another flagship offering, provides vital support to pediatric and adult patients suffering from bile acid synthesis disorders and serves as an adjunctive therapy for individuals with peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin-based tablets, are pivotal in managing homozygous cystinuria.
The company's robust pipeline includes promising candidates like Sparsentan, currently undergoing Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Another noteworthy candidate, TVT-058, a novel human enzyme replacement therapy, is in Phase I/II clinical trials for classical homocystinuria, underscoring Travere's commitment to pioneering treatments for complex genetic disorders.
Founded in 2008 and headquartered in San Diego, California, Travere Therapeutics, Inc. operates at the forefront of rare disease therapeutics. The company collaborates extensively with leading research institutions and patient advocacy organizations, such as the National Institutes of Health's National Center for Advancing Translational Sciences, CDG Care, and Alagille Syndrome Alliance, to drive innovative solutions for unmet medical needs in the rare disease community.